Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

19 citing papers in PubMed.

1. Decreased Anti-inflammatory IL-2 and IL-10 and Increased Mononuclear Cell Tissue Factor Correlate with Stroke Severity: Do Anti-inflammatory Cytokines Modulate Thrombosis?CNS & neurological disorders drug targets · 2026
   Article
2. Mutant IL-2-expressing mesenchymal stromal cells promote regulatory T cells proliferation and activation in collagen induced arthritis mice.Arthritis research & therapy · 2025
   Article
3. Comparison of Regulatory T-Cell Subpopulations in Antithymocytic Globulin Versus Post-Transplant Cyclophosphamide for Preventing Graft-Versus-Host Disease in Allogeneic Hematopoietic Stem Cell Transplantation-A Retrospective Study.International journal of molecular sciences · 2025
   Article
4. Herpesvirus Screening in Childhood Hematopoietic Transplant Reveals High Systemic Inflammation in Episodes of Multiple Viral Detection and an EBV Association with Elevated IL-1β, IL-8 and Graft-Versus-Host Disease.Microorganisms · 2022
   Article
5. Responses of regulatory and effector T-cells to low-dose interleukin-2 differ depending on the immune environment after allogeneic stem cell transplantation.Frontiers in immunology · 2022
   Article
6. The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes.JCI insight · 2021
   Article
7. Analysis of therapeutic potential of preclinical models based on DR3/TL1A pathway modulation (Review).Experimental and therapeutic medicine · 2021
   Review
8. Harnessing Treg Homeostasis to Optimize Posttransplant Immunity: Current Concepts and Future Perspectives.Frontiers in immunology · 2021
   Review
9. Prognostic significance of plasma IL-2 and sIL-2Rα in patients with first-ever ischaemic stroke.Journal of neuroinflammation · 2020
   Article
10. Transient antibody targeting of CD45RC inhibits the development of graft-versus-host disease.Blood advances · 2020
    Article
11. Sensitive Photodynamic Detection of Adult T-cell Leukemia/Lymphoma and Specific Leukemic Cell Death Induced by Photodynamic Therapy: Current Status in Hematopoietic Malignancies.Cancers · 2020
    Review
12. Rheumatological manifestations in inborn errors of immunity.Pediatric research · 2020
    Review
13. Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases.Journal of immunology (Baltimore, Md. : 1950) · 2019
    Review
14. Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17/Treg cells in refractory SLE patients.BMC immunology · 2019
    Article
15. The promise of CD4Haematologica · 2019
    Review
16. Relationship between clinical course of nivolumab-related myositis and immune status in a patient with Hodgkin's lymphoma after allogeneic hematopoietic stem cell transplantation.International journal of hematology · 2019
    Article
17. Superior immune reconstitution using Treg-expanded donor cells versus PTCy treatment in preclinical HSCT models.JCI insight · 2018
    Article
18. The immune response is a prerequisite for the development of CD4International journal of clinical and experimental pathology · 2018
    Article
19. Virotherapy as Potential Adjunct Therapy for Graft-Vs-Host Disease.Current pathobiology reports · 2018
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as